Domača stranRARE • NASDAQ
add
Ultragenyx Pharmaceutical Inc
Prejšnji trg. dan.
47,36 $
Dnevni razpon
47,04 $ - 47,82 $
Letni razpon
37,02 $ - 60,37 $
Tržna kapitalizacija
4,35 mrd. USD
Povprečni obseg
809,28 tis.
Razm. P/E
-
Dividendna donosnost
-
Primarna borza
NASDAQ
V novicah
Finančni podatki
Izkaz poslovnega izida
Prihodek
Čisti dohodek
| (USD) | sep. 2024info | Sprememba L/L |
|---|---|---|
Prihodek | 139,49 mio. | 42,27 % |
Stroški poslovanja | 250,46 mio. | 7,88 % |
Čisti dohodek | −133,52 mio. | 16,37 % |
Čista dobičkovnost prihodkov | −95,71 | 41,22 % |
Earnings per share | −1,40 | 37,22 % |
EBITDA | −123,23 mio. | 10,64 % |
Efektivna davčna stopnja | −0,23 % | — |
Bilanca stanja
Skupna sredstva
Skupne obveznosti
| (USD) | sep. 2024info | Sprememba L/L |
|---|---|---|
Denar. in kratkor. naložbe | 607,51 mio. | 37,42 % |
Skupna sredstva | 1,54 mrd. | 24,25 % |
Skupne obveznosti | 1,18 mrd. | −1,81 % |
Celoten lastniški kapital | 353,83 mio. | — |
Shares outstanding | 92,28 mio. | — |
Razmerje P/B | 12,60 | — |
Donosnost sredstev | −20,90 % | — |
Donosnost kapitala | −25,14 % | — |
Denarni tok
Neto sprememba denarnih sredstev
| (USD) | sep. 2024info | Sprememba L/L |
|---|---|---|
Čisti dohodek | −133,52 mio. | 16,37 % |
Denar iz dejavnosti | −67,00 mio. | 43,16 % |
Denar iz naložb | −275,50 mio. | −528,50 % |
Denar iz financiranja | 11,17 mio. | −55,72 % |
Neto sprememba denarnih sredstev | −330,05 mio. | −1.035,71 % |
Prost denarni tok | −23,26 mio. | 65,84 % |
Vizitka
Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.
Ultragenyx is based in Novato, CA and Brisbane, CA and has a presence in the Boston area, including a gene therapy plant under construction as of 2021. The company’s Latin American headquarters is located in Miami.
Ultragenyx collaborates on product development with other companies including GeneTX, Kyowa Hakko Kirin, Mereo Biopharma and Daiichi Sankyo. Ultragenyx has three products Burosumab, Triheptanoin and Vestronidase alfa that have received FDA approval and several others currently in clinical trials. The company also holds the non-US commercial rights to Regeneron’s evinacumab-dgnb, which is approved by the FDA and EMA. Wikipedia
Generalni direktor
Datum ustanovitve
2010
Sedež organizacije
Spletno mesto
Zaposleni
1.276
